BioSpace News Archive

Faster rate of regulatory approvals for canine separation anxiety treatments with developments in behavioral modification applications are key to growth in the sector.

Investments towards automation of supply management systems for forecasting demand with contingency plans will remain key to growth strategies in terms of sales.

This report analyzes the current and future scenario of the global brachytherapy devices market for the period 2018-2026.

The global positive airway pressure devices market is driven by high prevalence and rapid increase in incidence of sleep apnea across the globe.

ITM AG, a privately held radiopharmaceutical biotech company, announced that is has signed two strategic agreements with Telix Pharmaceuticals Limited for the global supply of ITM’s highly pure therapeutic radioisotope no-carrier-added Lutetium-177.

Long-term care homes have been at the epicentre of the COVID-19 pandemic in Canada, with 70 percent of COVID-19 deaths having occurred in long-term care or nursing homes.

Randomized, double-blind Phase 3 study to assess the efficacy and safety of GIVinostat versus hydroxyurea IN JAK2V617F-positive high-risk Polycythemia Vera patients (GIV-IN PV TRIAL) with over 100 participating international clinical sites to be initiated by mid-2021

Co-founded back in 2014 by VHIO’s Laura Soucek, CEO of the enterprise, and Marie-Eve Beaulieu, Chief Scientific Officer (CSO) of the company, VHIO-born spin-off Peptomyc S.L . has just announced that it has received approval from the Spanish Agency of Medicines and Medical Devices for conducting clinical trials in Spain (AEMPS), to initiate the first-in-human Phase I/II clinical trial with its first compound

NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY) announces it will report financial results for the three and 12 months ended December 31, 2020 after market close on Thursday, March 25, 2021 and will hold an investment community conference call that day at 4:30 p.m. Eastern time.

Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Marvin H. Johnson, Jr. has been appointed to the Company’s Board of Directors, and will stand for election at the 2021 Annual Meeting of Stockholders.